<div id="readability-page-1"><div>NEW YORK, Aug. 17, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of NeoGenomics, Inc. (“NeoGenomics” or the “Company”) (NASDAQ: NEO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether NeoGenomics and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action] July 29, 2025, NeoGenomics issued a press release reporting its financial results for the second quarter of 2025. Among other items, NeoGenomics reported revenue of $181.3 million, falling short of consensus estimates, and a net loss of $45.1 million. NeoGenomics also reduced its 2025 revenue forecast to a range of $720 million to $726 million, down from a previous estimate of approximately $753 million. In addition, NeoGenomics lowered its adjusted EBITDA projection to a range of $41 million to $44 million from a prior range of $55 million to $58 million. On this news, NeoGenomics’ stock price fell $1.21 per share, or 18.73%, to close at $5.25 per share on July 29, 2025. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com. Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT: Danielle Peyton Pomerantz LLP dpeyton@pomlaw.com 646-581-9980 ext. 7980 <img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RVeE1EQTVPU00zTURreU9ETXdJekl3TVRjMk5EUT0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RVeE1EQTVPU00zTURreU9ETXdJekl3TVRjMk5EUT0"/> <img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/Y2JhNmFkNTAtOTkyNC00Zjg3LWFkZmEtMDU4MTc4ZTczYTkwLTEwMjkyMTctMjAyNS0wOC0xNy1lbg==/tiny/Pomerantz-LLP.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/Y2JhNmFkNTAtOTkyNC00Zjg3LWFkZmEtMDU4MTc4ZTczYTkwLTEwMjkyMTctMjAyNS0wOC0xNy1lbg==/tiny/Pomerantz-LLP.png"/></div></div>

Pomerantz 律師事務所正在代表 NeoGenomics, Inc.（納斯達克代碼：NEO）的投資者調查有關該公司及其高管可能存在的證券欺詐的索賠。NeoGenomics 報告了令人失望的 2025 年第二季度財務業績，收入為 1.813 億美元，淨虧損為 4510 萬美元，導致股價下跌 18.73%，至每股 5.25 美元。該事務所以其在證券集體訴訟方面的專業知識而聞名，並且在為企業不當行為的受害者追回損失方面有着良好的歷史記錄

投資者警示：Pomerantz 律師事務所正在代表 Neogenomics, Inc. - NEO 的投資者進行索賠調查